Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 23Colorectal Neoplasms 11Colonic Neoplasms 8Carcinoma, Hepatocellular 6Rectal Neoplasms 5Pancreatic Neoplasms 5Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Biliary Tract Neoplasms 3HER2-positive Gastric Cancer 2Gallbladder Neoplasms 2Uterine Cervical Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lung Neoplasms 1Klatskin Tumor 1Immunotherapy 1Gastric Adenocarcinoma 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Epstein-Barr Virus Infections 1Efficacy and Safety 1

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Efficacy and Safety × Tegafur × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡